 | |
| Clinical data | |
|---|---|
| Trade names | Befol (RU) |
| Other names | Befol |
| Routes of administration | Oral |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H19ClN2O2 |
| Molar mass | 282.77 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Eprobemide (INN) is a pharmaceutical drug that was used as an antidepressant in Russia (under the brand name Бефол/Befol).[1] It is a non-competitive reversible inhibitor of monoamine oxidase A[2][3] that exhibits selective action on serotonin deamination.[4] Eprobemide differs from moclobemide only in the linker that connects the morpholine fragment with the chlorobenzamide — moclobemide has two carbon atoms while eprobemide has three. Its registration was cancelled on December 30, 2003.[5]
References
- ^ Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. Vol. 3. p. 811. ISBN 978-0412466304.
- ^ Gol'dina OA, Moskvitina TA, Gankina EM, Kirkel' AZ, Kamyshanskaia NS, Lopatina KI, et al. (March 1991). "[The action of befol and its derivatives on monoamine oxidase of different origins]". Biulleten' Eksperimental'noi Biologii I Meditsiny. 111 (3): 279–80. PMID 2054504.
- ^ Donskaya NS, Antonkina OA, Glukhan EN, Smirnov SK (2004-07-01). "Antidepressant Befol Synthesized Via Interaction of 4-Chloro-N-(3-chloropropyl)benzamide with Morpholine". Pharmaceutical Chemistry Journal. 0091-150X. 38 (7): 381–384. doi:10.1023/B:PHAC.0000048439.38383.5f. S2CID 29121452.
- ^ "Eprobemide". ChemIDplus.
- ^ "Befol". 4DOKTOR.RU Drug Information Handbook (in Russian). Retrieved 4 February 2014.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 19 November 2023, at 00:28